Press Releases

Press Releases

Share
Share
and/or
506 News Releases found
Lehigh Valley Health Network has become an official member of the MSK Cancer Alliance.
Lehigh Valley Health Network Cancer Institute Officially Named Second Member of the Memorial Sloan Kettering Cancer Alliance
The Lehigh Valley Health Network (LVHN) Cancer Institute is now a formal member of the Memorial Sloan Kettering (MSK) Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for people with cancer in community healthcare settings. Representatives of both organizations made the announcement today at Lehigh Valley Hospital–Cedar Crest following an intensive six-month collaborative review process.
Memorial Sloan Kettering Granted Prestigious ANCC Magnet Recognition®
Memorial Sloan Kettering Cancer Center (MSK) announced today that it has received Magnet® recognition, the nation’s highest honor for excellence in nursing. Granted by the American Nurses Credentialing Center (ANCC), Magnet® recognition is the most prestigious distinction a healthcare organization can receive for nursing excellence and quality patient outcomes. Only about 7 percent of hospitals nationally carry this prestigious designation.
Leaders from Baptist Health South Florida and Memorial Sloan Kettering today announced their recently signed agreement for Miami Cancer Institute to join the Memorial Sloan Kettering Cancer Alliance.
Miami Cancer Institute at Baptist Health South Florida Joins Memorial Sloan Kettering Cancer Alliance
Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care. Leaders from both institutions have confirmed the first step in announcing their recently signed agreement for Miami Cancer Institute to join the Memorial Sloan Kettering Cancer Alliance.
Memorial Sloan Kettering Joins Nation’s Cancer Centers in Endorsement of HPV Vaccination for Cancer Prevention
In response to low national vaccination rates for the human papillomavirus (HPV), Memorial Sloan Kettering Cancer Center (MSK) has joined with the 68 other National Cancer Institute (NCI)–designated cancer centers in <a href="/node/115951"> issuing a statement</a> urging for increased HPV vaccination for the prevention of cancer. These institutions collectively recognize insufficient vaccination as a public health threat and call upon the nation’s physicians, parents, and young adults to take advantage of this rare opportunity to prevent many types of cancer.
The Future of Outpatient Cancer Surgery Takes Shape with New, First-of-Its-Kind Facility
A major transformation is beginning in cancer surgery that will enable patients to go home within a day of undergoing a significant operation. The new Josie Robertson Surgery Center (JRSC), opened by Memorial Sloan Kettering, exemplifies that transformation: a patient-focused facility that leverages technology and highly trained clinical teams to provide optimal care.
Memorial Sloan Kettering Studies Highlight Potential of Liquid Biopsy at San Antonio Breast Cancer Symposium
Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.
Positive Data from Phase III Study Shows Combination Therapy with Idelalisib Is More Effective Versus Standard of Care in Treatment-Resistant Chronic Lymphocytic Leukemia
Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.
Philip W. Kantoff, MD, Named Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center
Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). An accomplished leader, physician, researcher, and mentor, Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School (HMS) since 1987 in a variety of capacities. He formally assumes his new position as George J. Bosl, MD, steps down from his role after 18 years.
Study Examines Cancer-Care Outcomes among US Hospitals
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
Three Young Investigators Named Winners of 2015 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research.